Development of c-MET pathway inhibitors

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor

(2010) B.-S. Pan et al.   CANCER RESEARCH

Clinical implications ofMETgene copy number in lung cancer

(2010) Luca Toschi et al.   Future Oncology

Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma

(2010) Pinar Topcu-Yilmaz et al.   MELANOMA RESEARCH

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

(2009) Sergei L. Timofeevski et al.   BIOCHEMISTRY

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

(2009) S Agarwal et al.   BRITISH JOURNAL OF CANCER

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

(2009) Takayuki Nakagawa et al.   CANCER SCIENCE

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Molecularly Targeted Therapies for Thyroid Cancers

(2009) Steven Sherman   Endocrine Practice

c-Met Confers Protection Against Chronic Liver Tissue Damage and Fibrosis Progression After Bile Duct Ligation in Mice

(2009) Arne Giebeler et al.   GASTROENTEROLOGY

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase–2 and –7 and E-cadherin

(2009) Yasuyoshi Miyata et al.   HUMAN PATHOLOGY

Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer

(2009) Jihong Ma et al.   JOURNAL OF CLINICAL INVESTIGATION

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

(2009) Gary J. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

(2009) Gretchen M. Schroeder et al.   JOURNAL OF MEDICINAL CHEMISTRY

HGF and MET Mutations in Primary and Secondary Lymphedema

(2009) David N. Finegold et al.   Lymphatic Research and Biology

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

(2009) S. G. Buchanan et al.   MOLECULAR CANCER THERAPEUTICS

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

(2009) M. G. Ponzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic significance of c-Met expression in glioblastomas

(2008) Doo-Sik Kong et al.   CANCER

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

(2008) Zhao-Shi Zeng et al.   CANCER LETTERS

Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo

(2008) Y. Zhang et al.   CANCER RESEARCH

552 POSTER Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design

(2008) P.A. Janne et al.   EJC SUPPLEMENTS

Targeting the c-MET signaling pathway for cancer therapy

(2008) Xiangdong Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Small molecule c-MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma

(2008) Chandrani Chattopadhyay et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Prevalence of Secondary Causes of Bone Loss Among Breast Cancer Patients With Osteopenia and Osteoporosis

(2008) Pauline M. Camacho et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma

(2008) Leina Etto et al.   LEUKEMIA & LYMPHOMA

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia

(2008) A. G. Zhelyazkova et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION